Atyr Pharma Inc. (ATYR)
NASDAQ:ATYR
Want to see ATYR full AI Analyst Report?
ATYR Stock Chart & Stats
$0.85
-$0.23(-5.91%)
At close: 4:00 PM EST
$0.85
-$0.23(-5.91%)
Day’s Range― - ―
52-Week Range$0.40 - $7.29
Previous CloseN/A
Volume346.43K
Average Volume (3M)3.31M
Market Cap
$53.19M
Enterprise Value$54.88M
Total Cash (Recent Filing)$66.51M
Total Debt (Recent Filing)$11.70M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 12, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding98,051,210
10 Day Avg. Volume4,126,890
30 Day Avg. Volume3,311,374
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue288.87
Enterprise Value/Gross Profit-2.46
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$6.38Price Target Upside650.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Clarity & Phase 3 PlanFDA Type C minutes giving clear endpoint guidance and patient-selection refinements materially reduce regulatory uncertainty for efzofitimod. A well-specified global Phase 3 with revised dosing and monitoring creates a more rigorous path to approval and long-term value realization if successful.
Relatively Conservative LeverageModest debt and positive equity provide structural financial flexibility versus more highly leveraged peers. While runway is constrained by burn, the low leverage reduces immediate solvency risk and gives management options (debt, partnerships) to fund pivotal-stage development without excessive near-term covenant pressure.
Differentiated Scientific PlatformA unique mechanism focused on extracellular aminoacyl-tRNA synthetases offers a structural competitive advantage; platform science can enable multiple inflammation indications. If clinical proof emerges, this differentiated biology supports durable franchise potential beyond a single asset, improving long-term commercial optionality.
Bears Say
Negligible Revenue And Large LossesMinimal revenue and sustained multi-year losses show the company lacks commercial cash flow, making operations fully development-funded. Persistent negative earnings erode equity over time, heightening reliance on external financing which can dilute shareholders and constrain long-term strategic flexibility.
Severe Cash Burn And Weak Cash GenerationHigh and worsening negative operating and free cash flow indicate ongoing funding needs to progress Phase 3 programs. This structural cash deficit increases probability of future equity raises or partnering under non-ideal terms, which can dilute existing holders and slow program timelines if funding gaps occur.
Prior Pivotal Miss Raises Clinical RiskA prior Phase 3 miss demonstrates tangible clinical execution and efficacy risk. Even with revised endpoints and dosing, historical failure increases uncertainty around reproducible benefit in large trials, making long-term approval and commercial success less certain until robust confirmatory data are reported.
aTyr Pharma News
ATYR FAQ
What was Atyr Pharma Inc.’s price range in the past 12 months?
Atyr Pharma Inc. lowest stock price was $0.40 and its highest was $7.29 in the past 12 months.
What is Atyr Pharma Inc.’s market cap?
Atyr Pharma Inc.’s market cap is $53.19M.
When is Atyr Pharma Inc.’s upcoming earnings report date?
Atyr Pharma Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 72 days.
How were Atyr Pharma Inc.’s earnings last quarter?
Atyr Pharma Inc. released its earnings results on May 15, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.022.
Is Atyr Pharma Inc. overvalued?
According to Wall Street analysts Atyr Pharma Inc.’s price is currently Undervalued.
Does Atyr Pharma Inc. pay dividends?
Atyr Pharma Inc. does not currently pay dividends.
What is Atyr Pharma Inc.’s EPS estimate?
Atyr Pharma Inc.’s EPS estimate is -0.12.
How many shares outstanding does Atyr Pharma Inc. have?
Atyr Pharma Inc. has 98,051,210 shares outstanding.
What happened to Atyr Pharma Inc.’s price movement after its last earnings report?
Atyr Pharma Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went down -9.839%.
Which hedge fund is a major shareholder of Atyr Pharma Inc.?
Currently, no hedge funds are holding shares in ATYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aTyr Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.38 (650.00% Upside)
$6.38 (650.00% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 250.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.26%
12-Months-Change
Fundamentals
Return on Equity
-99.87%
Trailing 12-Months
Asset Growth
-18.09%
Trailing 12-Months
Company Description
Atyr Pharma Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Stock 12 Month Forecast
Average Price Target
$6.38
▲(650.00% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
2.55% Insiders
26.57% Mutual Funds
0.47% Other Institutional Investors
62.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---